Actually, both revenue and income are proxies for the relevant number, given that I had in mind to address the GP's point of 'effectively funding a significant portion of R&D.' If the article [0] is to be believed, that's about 8-9 Billion for Pfizer, and about 70 Billion for the top 15 pharma companies, about 2% of US health care spending. Even if we cut US health care spending in half (to, say, the UK's level), funding pharma research at current levels would be a fraction of total costs.
